Epigenetic therapies for the treatment of acute myeloid leukemia

Lead researcher

Prof Ricky Johnstone

Peter MacCallum Cancer Centre

Years funded

This project aims to identify new treatments for people with acute myeloid leukemia (AML). AML is a disease that can be driven by changes in gene expression through a process called epigenetics. We aim to utilise pre-clinical models of human AML to test new agents that reverse the epigenetic changes that occur in this disease. Ultimately we aim to introduce these new treatment regimens into the clinic.

Lay Report - Final

Epigenetic-based therapies for AML

Funding Body

Cancer Council Research Grant


$98,723 per annum